Remdesivir in renal transplant patients with coronavirus disease 2019: An observational study

Muzamil Latief; Farhat Abbas; Mohd Iqbal; Zhahid Hassan; L Naresh Goud; Obeid Shafi

doi:10.4103/ijot.ijot_54_21

Users Online: 314

ORIGINAL ARTICLE

Year : 2022 \| Volume : 16 \| Issue : 2 \| Page : 216-219

Remdesivir in renal transplant patients with coronavirus disease 2019: An observational study Muzamil Latief¹, Farhat Abbas², Mohd Iqbal³, Zhahid Hassan⁴, L Naresh Goud⁵, Obeid Shafi⁶ ¹ Division of Nephrology, Superspecialty Hospital, Government Medical College, Srinagar, Jammu and Kashmir, India ² Division of Pathology, Government Medical College, Srinagar, Jammu and Kashmir, India ³ Division of Nephrology, ASCOMS Hospital, Jammu, Jammu and Kashmir, India ⁴ Department of Medicine, Government Medical College, Baramula, Jammu and Kashmir, India ⁵ Department of Pharmacy Practice, Nova College of Pharmaceutical Education and Research, Hyderabad, Telangana, India ⁶ Flushing Hospital Medical Center, New York, USA Correspondence Address: Dr. Muzamil Latief Division of Nephrology, Superspecialty Hospital, Government Medical College, Srinagar - 190 010, Jammu and Kashmir India Source of Support: None, Conflict of Interest: None DOI: 10.4103/ijot.ijot_54_21

Introduction: Remdesivir has shown broad-spectrum antiviral activity. This drug is approved by the Food and Drug Administration for coronavirus disease 2019 (COVID-19) management. Other than a few case series and case reports, not much information is available on its use in kidney transplant recipients (KTRs). Materials and Methods: We describe our experience of seven KTRs with COVID-19. All the patients were hypoxemic. High-resolution computed tomography (CT) chest was done in all the patients. Injection remdesivir 200 mg on day 1 followed by 100 mg daily was given for a maximum of 5 days irrespective of estimated glomerular filtration rate (eGFR). Observations and Results: Mean age of patients was 46.28 ± 10.41 years and one patient was female. Mean CT severity score was 15. In our study, 2 patients who required mechanical ventilation expired. None of our patient had worsening of acute kidney injury (AKI) or new-onset AKI after institution of remdesivir. Discussion: Optimal management for this patient population remains unknown, therefore, treatment of COVID-19 in KTRs varies from center to center. The studies on remdesivir use in KTRs with COVID-19 are not extensive. Our series does indicate safety of remdesivir in KTRs. Conclusion: We observed that remdesivir can be used in KTRs with COVID-19 with hypoxemia irrespective of eGFR. We suggest that large-scale studies should be done to substantiate these findings.



[FULL TEXT] [PDF]*

Table of Contents

Similar in PUBMED

Search Pubmed for

Search in Google Scholar for

Related articles

Citation Manager

Access Statistics

Reader Comments

Email Alert *

Add to My List *

* Requires registration (Free)

Article Access Statistics

Viewed	146

Printed	4

Emailed	0

PDF Downloaded	22

Comments	[Add]